Study 24 of 34Retatrutide (LY3437943) literatureBMJ (Clinical research ed.)Top journal2026
Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.
Not reported in abstract.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpus14
Preclinical · this one
7
Observational
0
Open-label
6
Randomised
7
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Elsewhere in the Retatrutide (LY3437943) corpus
DGLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases.European journal of pharmacology · 2026reviewARetatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.The New England journal of medicine · 2026 · -34.3 events/hour AHI change with 9 mg retatrutide vs -9.9 with placebo in TRIUMPH-1-OSA, difference vs placebo -24.4 (95% CI, -34.1 to -14.7)HumanDUnapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.JAMA · 2026—DUnapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.JAMA · 2026—DRetatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?Lancet (London, England) · 2026—DRetatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.BMJ (Clinical research ed.) · 2026—